Portal de Periódicos da CAPES

The type of SARS‐CoV‐2 vaccine influences serological response in kidney transplant recipients

2022; Wiley; Volume: 36; Issue: 4 Linguagem: Inglês

10.1111/ctr.14585

1399-0012

Ana Luísa Correia, Rita Leal, Ana Carolina Pimenta, Mariana Fernandes, Maria Guedes Marques, Luís Rodrigues, Lídia Santos, Catarina Romãozinho, Susana Machado, Jorge Pratas, Lucília Araújo, Arnaldo Figueiredo, Rui Alves,

Animal Virus Infections Studies

Abstract Vaccination is a promising strategy to control the ongoing pandemic; however, solid organ recipients tend to develop a weaker immune response to vaccination. Anti‐spike SARS‐CoV‐2 antibodies titers were measured 2–4 weeks post‐vaccination completion in 131 KT patients without previous infection. Demographic, clinical, and laboratorial parameters were analyzed to identify which factors contributed to seroconversion. Factors that influenced seroconversion, that occurred in 76 patients (58%), were longer time post‐transplant, immunosuppression without an antiproliferative drug and vaccination with mRNA vaccines. Patients who received mRNA vaccines had significantly higher rates of seroconversion compared with adenovirus vector vaccines (67% vs 33%, P < .001) and higher anti‐spike IgG titers. These findings reinforce the need to discuss the vaccination strategy in this population, including a third dose with a mRNA vaccine.